Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy
Saved in:
Main Authors: | Madhan Krishnan, Shyamaladevi Babu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-09-01
|
Series: | Oral Oncology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004874 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Catalysts of change: Immunotherapy's frontier in oral oncology
by: Shyamaladevi Babu, et al.
Published: (2024-09-01) -
Advancements in immunotherapy: Transforming the landscape of oral cancer treatment
by: Madhan Krishnan, et al.
Published: (2024-09-01) -
Biomarkers in Nasopharyngeal Carcinoma (NPC): Clinical relevance and prognostic potential
by: Madhan Krishnan, et al.
Published: (2024-09-01) -
Exploring the influence of Interleukin-1 ligand expression in head and neck squamous cell carcinoma
by: Madhan Krishnan, et al.
Published: (2024-06-01) -
Customized immunotherapy in OSCC: Leveraging neoantigens for precision medicine
by: Dr. Nitya Krishnasamy, et al.
Published: (2024-12-01)